Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment

Science Translational Medicine

Volumn 3, Issue 73, 2011, Pages

  Chow, Edward K ^a   Zhang, Xue Qing ^b   Chen, Mark ^c   Lam, Robert ^b   Robinson, Erik ^b   Huang, Houjin ^b   Schaffer, Daniel ^b   Osawa, Eiji ^d   Goga, Andrei ^e   Ho, Dean ^b,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Northwestern University   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d SHINSHU UNIVERSITY   (Japan)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; NANOCARRIER; NANODIAMOND; UNCLASSIFIED DRUG; ABC TRANSPORTER; ANTINEOPLASTIC AGENT; DIAMOND; DRUG CARRIER; NANOMATERIAL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOCOMPATIBILITY; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER RESISTANCE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG SAFETY; HEPATOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECT; DRUG RESISTANCE; EXPERIMENTAL NEOPLASM; FEMALE; LIVER TUMOR; METABOLISM; NANOMEDICINE; NANOTECHNOLOGY; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; DIAMOND; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NANOMEDICINE; NANOSTRUCTURES; NANOTECHNOLOGY; NEOPLASMS, EXPERIMENTAL;

EID: 79952461058     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001713     Document Type: Article

References (49)

1. S. Kawai, J. Okamura, M. Ogawa, Y. Ohashi, M. Tani, J. Inoue, Y. Kawarada, M. Kusano, Y. Kubo, C. Kuroda, Y. Sakata, Y. Shimamura, K. Jinno, A. Takahashi, K. Takayasu, K. Tamura, N. Nagasue, Y. Nakanishi, M. Makino, M. Masuzawa, S. Mikuriya, M. Monden, Y. Yumoto, T. Mori, T. Oda; The Cooperative Study Group for Liver Cancer Treatment of Japan, Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma - a comparison of lipiodol-transcatheter arterial embolization with and without Adriamycin (first cooperative study). Cancer Chemother. Pharmacol. 31, S1-S6 (1992).
2. D. B. Longley, P. G. Johnston, Molecular mechanisms of drug resistance. J. Pathol. 205, 275-292 (2005).
3. P. D. Eckford, F. J. Sharom, ABC efflux pump-based resistance to chemotherapy drugs. Chem. Rev. 109, 2989-3011 (2009).
4. F. Thiebaut, T. Tsuruo, H. Hamada, M. M. Gottesman, I. Pastan, M. C. Willingham, Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U.S.A. 84, 7735-7738 (1987).
5. 2) into milk. Mol. Cell. Biol. 27, 1247-1253 (2007).
6. J. A. Kruger, C. D. Kaplan, Y. Luo, H. Zhou, D. Markowitz, R. Xiang, R. A. Reisfeld, Characterization of stem cell-like cancer cells in immune-competent mice. Blood 108, 3906-3912 (2006).
7. K. Mross, C. Bohn, L. Edler, W. Jonat, W. Queisser, E. Heidemann, M. Goebel, D. K. Hossfeld, Randomized phase II study of single-agent epirubicin +/- verapamil in patients with advanced metastatic breast cancer. An AIO clinical trial. Arbeitsgemeinschaft Internistische Onkologie of the German Cancer Society. Ann. Oncol. 4, 45-50 (1993).
8. S. M. Kornblau, E. Estey, T. Madden, H. T. Tran, S. Zhao, U. Consoli, V. Snell, G. Sanchez-Williams, H. Kantarjian, M. Keating, R. A. Newman, M. Andreeff, Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J. Clin. Oncol. 15, 1796-1802 (1997).
9. A. M. Gobin, M. H. Lee, N. J. Halas, W. D. James, R. A. Drezek, J. L. West, Near-infrared resonant nanoshells for combined optical imaging and photothermal cancer therapy. Nano Lett. 7, 1929-1934 (2007).
10. C. Hom, J. Lu, M. Liong, H. Luo, Z. Li, J. I. Zink, F. Tamanoi, Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells. Small 6, 1185-1190 (2010).
11. T. J. Deming, Methodologies for preparation of synthetic block copolypeptides: Materials with future promise in drug delivery. Adv. Drug Deliv. Rev. 54, 1145-1155 (2002).
12. D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, R. Langer, Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751-760 (2007).
13. Z. Liu, J. T. Robinson, X. Sun, H. Dai, PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. J. Am. Chem. Soc. 130, 10876-10877 (2008).
14. K. Kostarelos, L. Lacerda, G. Pastorin, W. Wu, S. Wieckowski, J. Luangsivilay, S. Godefroy, D. Pantarotto, J. P. Briand, S. Muller, M. Prato, A. Bianco, Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. Nat. Nanotechnol. 2, 108-113 (2007).
15. N. R. Soman, S. L. Baldwin, G. Hu, J. N. Marsh, G. M. Lanza, J. E. Heuser, J. M. Arbeit, S. A. Wickline, P. H. Schlesinger, Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. J. Clin. Invest. 119, 2830-2842 (2009).
16. M. E. Davis, J. E. Zuckerman, C. H. Choi, D. Seligson, A. Tolcher, C. A. Alabi, Y. Yen, J. D. Heidel, A. Ribas, Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070 (2010).
17. X. Q. Zhang, M. Chen, R. Lam, X. Xu, E. Osawa, D. Ho, Polymer-functionalized nanodiamond platforms as vehicles for gene delivery. ACS Nano 3, 2609-2616 (2009).
18. M. Chen, E. D. Pierstorff, R. Lam, S. Y. Li, H. Huang, E. Osawa, D. Ho, Nanodiamond-mediated delivery of water-insoluble therapeutics. ACS Nano 3, 2016-2022 (2009).
19. H. Huang, E. Pierstorff, E. Osawa, D. Ho, Active nanodiamond hydrogels for chemotherapeutic delivery. Nano Lett. 7, 3305-3314 (2007).
20. M. V. Korobov, N. V. Avramenko, A. G. Bogachev, N. N. Rozhkova, E. Osawa, Nanophase of water in nano-diamond gel. J. Phys. Chem. C 111, 7330-7334 (2007).
21. E. Osawa, D. Ho, H. Huang, M. V. Korobov, N. N. Rozhkova, Consequences of strong and diverse electrostatic potential fields on the surface of detonation nanodiamond particles. Diam. Rel. Mat. 18, 904-909 (2009).
22. F. Neugart, A. Zappe, F. Jelezko, C. Tietz, J. P. Boudou, A. Krueger, J. Wrachtrup, Dynamics of diamond nanoparticles in solution and cells. Nano Lett. 7, 3588-3591 (2007).
23. J. I. Chao, E. Perevedentseva, P. H. Chung, K. K. Liu, C. Y. Cheng, C. C. Chang, C. L. Cheng, Nanometer-sized diamond particle as a probe for biolabeling. Biophys. J. 93, 2199-2208 (2007).
24. C. C. Fu, H. Y. Lee, K. Chen, T. S. Lim, H. Y.Wu, P. K. Lin, P. K. Wei, P. H. Tsao, H. C. Chang,W. Fann, Characterization and application of single fluorescent nanodiamonds as cellular biomarkers. Proc. Natl. Acad. Sci. U.S.A. 104, 727-732 (2007).
25. W. Yang, O. Auciello, J. E. Butler, W. Cai, J. A. Carlisle, J. E. Gerbi, D. M. Gruen, T. Knickerbocker, T. L. Lasseter, J. N. Russell Jr., L. M. Smith, R. J. Hamers, DNA-modified nanocrystalline diamond thin-films as stable, biologically active substrates. Nat. Mater. 1, 253-257 (2002).
26. W. S. Yeap, Y. Y. Tan, K. P. Loh, Using detonation nanodiamond for the specific capture of glycoproteins. Anal. Chem. 80, 4659-4665 (2008).
27. F. J. Sharom, ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomics 9, 105-127 (2008).
28. R. E. Eliaz, S. Nir, C. Marty, F. C. Szoka Jr., Determination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes. Cancer Res. 64, 711-718 (2004).
29. D. E. Koppel, Analysis of macromolecular polydispersity in intensity correlation spectroscopy: The method of cumulants. J. Chem. Phys. 57, 4814-4820 (1972).
30. B. J. Frisken, Revisiting the method of cumulants for the analysis of dynamic light-scattering data. Appl. Opt. 40, 4087-4091 (2001).
31. I. Pastan, M. M. Gottesman, K. Ueda, E. Lovelace, A. V. Rutherford, M. C. Willingham, A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc. Natl. Acad. Sci. U.S.A. 85, 4486-4490 (1988).
32. Y. Zen, T. Fujii, S. Yoshikawa, H. Takamura, T. Tani, T. Ohta, Y. Nakanuma, Histological and culture studies with respect to ABCG2 expression support the existence of a cancer cell hierarchy in human hepatocellular carcinoma. Am. J. Pathol. 170, 1750-1762 (2007).
33. T. Hiraga, S. Ito, H. Nakamura, Side population in MDA-MB-231 human breast cancer cells exhibits cancer stem cell-like properties without higher bone-metastatic potential. Oncol. Rep. 25, 289-296 (2011).
34. A. Goga, D. Yang, A. D. Tward, D. O. Morgan, J. M. Bishop, Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat. Med. 13, 820-827 (2007).
35. Z. Liu, K. Chen, C. Davis, S. Sherlock, Q. Cao, X. Chen, H. Dai, Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res. 68, 6652-6660 (2008).
36. Y. Yuan, Y. Chen, J. H. Liu, H. Wang, Y. Liu, Biodistribution and fate of nanodiamonds in vivo. Diam. Rel. Mat. 18, 95-100 (2009).
37. M. Chen, X.-Q. Zhang, H. B. Man, R. Lam, E. K. Chow, D. Ho, Nanodiamond vectors functionalized with polyethylenimine for siRNA delivery. J. Phys. Chem. Lett. 1, 3167-3171 (2010).
38. N. W. Kam, M. O'Connell, J. A. Wisdom, H. Dai, Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc. Natl. Acad. Sci. U.S.A. 102, 11600-11605 (2005).
39. N. A. Monteiro-Riviere, R. J. Nemanich, A. O. Inman, Y. Y. Wang, J. E. Riviere, Multi-walled carbon nanotube interactions with human epidermal keratinocytes. Toxicol. Lett. 155, 377-384 (2005).
40. T. R. Pisanic II, J. D. Blackwell, V. I. Shubayev, R. R. Fiñones, S. Jin, Nanotoxicity of iron oxide nanoparticle internalization in growing neurons. Biomaterials 28, 2572-2581 (2007).
41. 2 particles: Differential responses related to surface properties. Toxicology 230, 90-104 (2007).
42. M. E. Rostad, Current strategies for managing myelosuppression in patients with cancer. Oncol. Nurs. Forum 18, 7-15 (1991).
43. A. S. Barnard, M. Sternberg, Crystallinity and surface electrostatics of diamond nanocrystals. J. Mat. Chem. 17, 4811-4819 (2007).
44. T. Tyler, V. V. Zhirnov, A. V. Kvit, D. Kang, J. J. Hren, Electron emission from diamond nanoparticles on metal tips. App. Phys. Lett. 82, 2904-2906 (2003).
45. A. S. Barnard, Self-assembly in nanodiamond agglutinates. J. Mat. Chem. 18, 4038-4041 (2008).
46. E. Nakamura, K. Makino, T. Okano, T. Yamamoto, M. Yokoyama, A polymeric micelle MRI contrast agent with changeable relaxivity. J. Control Release 114, 325-333 (2006).
47. W. J. Mulder, R. Koole, R. J. Brandwijk, G. Storm, P. T. Chin, G. J. Strijkers, C. de Mello Donegá, K. Nicolay, A. W. Griffioen, Quantum dots with a paramagnetic coating as a bimodal molecular imaging probe. Nano Lett. 6, 1-6 (2006).
48. E. Tóth, R. D. Bolskar, A. Borel, G. González, L. Helm, A. E. Merbach, B. Sitharaman, L. J.Wilson, Water-soluble gadofullerenes: Toward high-relaxivity, pH-responsive MRI contrast agents. J. Am. Chem. Soc. 127, 799-805 (2005).
49. C. M. Shachaf, A. M. Kopelman, C. Arvanitis, A. Karlsson, S. Beer, S. Mandl, M. H. Bachmann, A. D. Borowsky, B. Ruebner, R. D. Cardiff, Q. Yang, J. M. Bishop, C. H. Contag, D. W. Felsher, MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431, 1112-1117 (2004).